October 2026
Second Round of Funding Between Ovesco Endoscopy AG and Trans-Duodenal Concepts GmbH
Tübingen, October 14, 2026. Ovesco Endoscopy AG and Trans-Duodenal Concepts GmbH are expanding their partnership. In a second round of financing, Ovesco Endoscopy is investing 1.1 million euros and increasing its stake in Trans-Duodenal Concepts GmbH to 25%. The investment will be used, among other things, to conduct a clinical trial and prepare for production.
Trans-Duodenal Concepts GmbH is developing an endoscopically implantable tubular prosthesis that lines the duodenum, thereby preventing the absorption of nutrients in the upper small intestine. This promotes weight loss and, for example, improves blood sugar management in patients with diabetes. The prosthesis can be removed after six months. With BARS®, a product designed to reduce dilated anastomoses—such as those that occur after gastric bypass surgery—Ovesco Endoscopy AG has already established itself in the endoscopic treatment of complications following bariatric procedures.
“With our solution, we are bridging the gap between conservative therapy and highly invasive surgical treatment for obesity,” explains Prof. Dr. med. Georg Kähler, founder of Trans-Duodenal Concepts GmbH. “With the investment from Ovesco Endoscopy, we will, among other things, conduct a study at eight hospitals; we are currently recruiting patients with type 2 diabetes mellitus at seven centers for this study.”
“At Ovesco, we drive innovation not only through our own products but also through strategic partnerships such as the one with Trans-Duodenal Concepts GmbH. We see enormous potential here to offer patients a new, minimally invasive option. This investment strengthens our partnership and accelerates the clinical development of a promising product,” said Prof. Dr. med. Marc Schurr, CEO of Ovesco Endoscopy AG.
About Trans-Duodenal Concepts GmbH
TDC is a startup affiliated with Heidelberg University and was founded by Prof. Dr. med. Georg Kähler, an internationally recognized endoscopist and long-time head of the Interdisciplinary Endoscopy Department at Mannheim University Hospital. With its innovative implant, the company aims to provide patients with diabetes and metabolic syndrome a minimally invasive and reversible treatment option. The procedure is now undergoing final evaluation in a multicenter study.
About Ovesco Endoscopy AG
Ovesco Endoscopy AG’s core competency lies in the development of endoluminal procedures and technologies that offer significant benefits to patients and clinicians in the treatment of gastrointestinal diseases. Every day, our employees work to develop innovative products of outstanding quality that deliver exceptional value to our customers and bring them to clinical practice. Ovesco develops, manufactures, and markets instruments and systems for the treatment of gastrointestinal diseases.